Back to Search
Start Over
Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience.
- Source :
-
BMC Cancer . 1/29/2020, Vol. 20 Issue 1, p1-8. 8p. 3 Diagrams, 4 Charts. - Publication Year :
- 2020
-
Abstract
- <bold>Background: </bold>The antibody targeting platelet-derived growth factor receptor alpha (PDGFRA), olaratumab, was approved in 2016 for metastatic soft tissue sarcoma (STS) in combination with doxorubicin based on promising results of a phase Ib/II trial by the Food and Drug Administration (FDA). However, recently the phase III ANNOUNCE trial could not confirm the additional value of olaratumab in this context.<bold>Methods: </bold>Here, in a retrospective analysis we share our single-centre experience with olaratumab/doxorubicin in STS by including n = 32 patients treated with olaratumab/doxorubicin between 2016 and 2019.<bold>Results: </bold>Median progression-free survival (PFS) in the overall cohort was 3.1 months (range 0.6-16.2). A response [complete remission (CR), partial remission (PR) or stable disease (SD)] was seen in n = 11 (34%) cases, whereas n = 21 (66%) patients showed progressive disease (PD). In n = 9 patients surgery was performed subsequently in an individual therapeutic approach. Out of n = 5 patients receiving additional regional hyperthermia, n = 3 achieved PR or SD.<bold>Conclusions: </bold>This single-centre experience does also not support the promising phase Ib/II results for olaratumab/doxorubicin in STS. However, our findings do not preclude that olaratumab combination therapy could be valuable in a neoadjuvant setting. This warrants further exploration also taking into account the heterogeneous nature of STS. [ABSTRACT FROM AUTHOR]
- Subjects :
- *SARCOMA
*PLATELET-derived growth factor receptors
*ISOLATION perfusion
*THERAPEUTIC use of antineoplastic agents
*DOXORUBICIN
*RETROSPECTIVE studies
*ANTINEOPLASTIC agents
*MONOCLONAL antibodies
*METASTASIS
*SOFT tissue tumors
*TUMOR classification
*TREATMENT effectiveness
*COMBINED modality therapy
*TUMOR grading
Subjects
Details
- Language :
- English
- ISSN :
- 14712407
- Volume :
- 20
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- BMC Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 141452248
- Full Text :
- https://doi.org/10.1186/s12885-020-6551-y